Fig. 4.
Overall survival from the time of inclusion in the LNH-87 trial. Comparison of patients with ALCL of T-cell type (n = 49) and patients with non-ALCL of T-cell type (n = 144); P = .0061.
Overall survival from the time of inclusion in the LNH-87 trial. Comparison of patients with ALCL of T-cell type (n = 49) and patients with non-ALCL of T-cell type (n = 144); P = .0061.
